Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. more
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | 0.67% | 0.6% |
| 1-Month Return | 2.51% | 3.45% |
| 3-Month Return | 19.93% | 3.96% |
| 6-Month Return | 30.51% | 13.85% |
| 1-Year Return | 134.24% | 20.6% |
| 3-Year Return | 139.55% | 73.65% |
| 5-Year Return | 20.58% | 73.98% |
| 10-Year Return | 150.51% | 255.61% |
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | 41.65% | 36.60% |
| 1-Month Return | 35.20% | 51.08% |
| 3-Month Return | 108.98% | 17.06% |
| 6-Month Return | 71.59% | 30.09% |
| 1-Year Return | 134.24% | 20.60% |
| 3-Year Return | 33.80% | 20.20% |
| 5-Year Return | 3.81% | 11.71% |
| 10-Year Return | 9.62% | 13.53% |
| Stock name | Ticker | Weight |
|---|---|---|
First Tracks Biotherapeutics Inc | TRAX | 1.56% |
AbCellera Biologics Inc | ABCL | 1.31% |
MBX Biosciences Inc | MBX | 1.18% |
Xencor Inc | XNCR | 1.17% |
AtaiBeckley Inc | ATAI | 1.16% |
Monopar Therapeutics Inc | MNPR | 1.15% |
Definium Therapeutics Inc | DFTX | 1.11% |
Replimune Group Inc | REPL | 1.07% |
uniQure NV | QURE | 1.07% |
ORIC Pharmaceuticals Inc | ORIC | 1.04% |
Vor BioPharma Inc | VOR | 1.01% |
Nurix Therapeutics Inc | NRIX | 1% |
REGENXBIO Inc | RGNX | 1% |
SELLAS Life Sciences Group Inc | SLS | 0.99% |
LB Pharmaceuticals Inc | LBRX | 0.97% |
Jade Biosciences Inc | JBIO | 0.97% |
Oruka Therapeutics Inc | ORKA | 0.97% |
Amylyx Pharmaceuticals Inc | AMLX | 0.96% |
Apogee Therapeutics Inc | APGE | 0.95% |
Alto Neuroscience Inc | ANRO | 0.94% |
Damora Therapeutics Inc | DMRA | 0.92% |
Zenas Biopharma Inc | ZBIO | 0.92% |
Palvella Therapeutics Inc | PVLA | 0.9% |
Immunome Inc | IMNM | 0.9% |
Cullinan Therapeutics Inc | CGEM | 0.9% |
Dyne Therapeutics Inc | DYN | 0.89% |
Praxis Precision Medicines Inc | PRAX | 0.86% |
Candel Therapeutics Inc | CADL | 0.86% |
Sana Biotechnology Inc | SANA | 0.86% |
SpyGlass Pharma Inc | SGP | 0.85% |
Celldex Therapeutics Inc | CLDX | 0.85% |
Relay Therapeutics Inc | RLAY | 0.84% |
Viridian Therapeutics Inc | VRDN | 0.84% |
Dianthus Therapeutics Inc | DNTH | 0.83% |
GH Research PLC | GHRS | 0.83% |
Kymera Therapeutics Inc | KYMR | 0.83% |
MeiraGTx Holdings plc | MGTX | 0.83% |
4D Molecular Therapeutics Inc | FDMT | 0.82% |
Avalo Therapeutics Inc | AVTX | 0.82% |
Biohaven Ltd | BHVN | 0.82% |
Achieve Life Sciences Inc | ACHV | 0.82% |
Revolution Medicines Inc | RVMD | 0.82% |
Design Therapeutics Inc | DSGN | 0.82% |
Assembly Biosciences Inc | ASMB | 0.82% |
Immix Biopharma Inc | IMMX | 0.81% |
Climb Bio Inc | CLYM | 0.8% |
Nektar Therapeutics | NKTR | 0.8% |
Structure Therapeutics Inc | GPCR | 0.8% |
Solid Biosciences Inc | SLDB | 0.79% |
Erasca Inc | ERAS | 0.79% |
Corvus Pharmaceuticals Inc | CRVS | 0.79% |
Ideaya Biosciences Inc | IDYA | 0.79% |
Spyre Therapeutics Inc | SYRE | 0.79% |
Enliven Therapeutics Inc | ELVN | 0.79% |
Septerna Inc | SEPN | 0.78% |
CG oncology Inc | CGON | 0.78% |
Adlai Nortye Ltd | ANL | 0.78% |
Immunovant Inc | IMVT | 0.78% |
Vaxcyte Inc | PCVX | 0.78% |
Edgewise Therapeutics Inc | EWTX | 0.78% |
Rapport Therapeutics Inc | RAPP | 0.77% |
Xenon Pharmaceuticals Inc | XENE | 0.77% |
Neurogene Inc | NGNE | 0.77% |
Lexicon Pharmaceuticals Inc | LXRX | 0.76% |
Rocket Pharmaceuticals Inc | RCKT | 0.76% |
Generate Biomedicines Inc | GENB | 0.76% |
Arcus Biosciences Inc | RCUS | 0.76% |
Belite Bio Inc | BLTE | 0.75% |
Scholar Rock Holding Corp | SRRK | 0.75% |
Aura Biosciences Inc | AURA | 0.75% |
BridgeBio Oncology Therapeutics Inc | BBOT | 0.74% |
Arvinas Inc | ARVN | 0.74% |
Janux Therapeutics Inc | JANX | 0.74% |
Disc Medicine Inc | IRON | 0.74% |
Kodiak Sciences Inc | KOD | 0.73% |
Oculis Holding AG | OCS | 0.72% |
VeraDermics Inc | MANE | 0.72% |
Maze Therapeutics Inc | MAZE | 0.72% |
Rezolute Inc | RZLT | 0.72% |
Viking Therapeutics Inc | VKTX | 0.72% |
Prime Medicine Inc | PRME | 0.71% |
Lexeo Therapeutics Inc | LXEO | 0.71% |
Upstream Bio Inc | UPB | 0.71% |
Cogent Biosciences Inc | COGT | 0.7% |
Tectonic Therapeutic Inc | TECX | 0.7% |
Annexon Inc | ANNX | 0.7% |
Compass Therapeutics Inc | CMPX | 0.7% |
CytomX Therapeutics Inc | CTMX | 0.7% |
Pharvaris NV | PHVS | 0.69% |
Mineralys Therapeutics Inc | MLYS | 0.69% |
Altimmune Inc | ALT | 0.69% |
Prothena Corp PLC | PRTA | 0.69% |
Compass Pathways Plc | CMPS | 0.69% |
Bicara Therapeutics Inc | BCAX | 0.68% |
Aktis Oncology Inc | AKTS | 0.68% |
Arbutus Biopharma Corp | ABUS | 0.67% |
Olema Pharmaceuticals Inc | OLMA | 0.67% |
Inhibrx Biosciences Inc | INBX | 0.66% |
Recursion Pharmaceuticals Inc | RXRX | 0.66% |
Stoke Therapeutics Inc | STOK | 0.66% |
Taysha Gene Therapies Inc | TSHA | 0.66% |
Vir Biotechnology Inc | VIR | 0.65% |
Allogene Therapeutics Inc | ALLO | 0.65% |
EyePoint Inc | EYPT | 0.65% |
Immatics NV | IMTX | 0.64% |
Alumis Inc | ALMS | 0.63% |
Savara Inc | SVRA | 0.63% |
Summit Therapeutics Inc | SMMT | 0.62% |
AnaptysBio Inc | ANAB | 0.62% |
Bicycle Therapeutics PLC | BCYC | 0.61% |
ArriVent Biopharma Inc | AVBP | 0.61% |
Celcuity Inc | CELC | 0.61% |
Intellia Therapeutics Inc | NTLA | 0.61% |
Crescent Biopharma Inc | CBIO | 0.58% |
Tyra Biosciences Inc | TYRA | 0.58% |
Beam Therapeutics Inc | BEAM | 0.57% |
Cabaletta Bio Inc | CABA | 0.56% |
Invivyd Inc | IVVD | 0.56% |
Wave Life Sciences Inc | WVE | 0.55% |
MoonLake Immunotherapeutics | MLTX | 0.55% |
Newamsterdam Pharma Co NV | NAMS | 0.55% |
Monte Rosa Therapeutics Inc | GLUE | 0.54% |
ProKidney Corp | PROK | 0.54% |
Vera Therapeutics Inc | VERA | 0.53% |
Tango Therapeutics Inc | TNGX | 0.52% |
Relmada Therapeutics Inc | RLMD | 0.45% |
Evommune Inc | EVMN | 0.44% |
BioAge Labs Inc | BIOA | 0.36% |
MapLight Therapeutics Inc | MPLT | 0.26% |
Cash/Cash equivalents | Cash.Cash.equivalents | 0.12% |
Sionna Therapeutics Inc | SION | 0.11% |
Capricor Therapeutics Inc | CAPR | 0.1% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
Virtus LifeSci Biotech Clinical Trials ETF (BBC) share price today is $52.8675.
Yes, Indians can buy shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. To buy BBC from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. You can start investing in Virtus LifeSci Biotech Clinical Trials ETF (BBC) with a minimum investment of $1.
The 52-week high price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $54.95. The 52-week low price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $21.47.
The stock symbol (or ticker) of Virtus LifeSci Biotech Clinical Trials ETF is BBC.
Yes, you can setup SIP in Virtus LifeSci Biotech Clinical Trials ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of BBC on the Vested app.
The expense ratio of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is 0.79%.
Link copied